ATE536178T1 - Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis - Google Patents

Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis

Info

Publication number
ATE536178T1
ATE536178T1 AT04810055T AT04810055T ATE536178T1 AT E536178 T1 ATE536178 T1 AT E536178T1 AT 04810055 T AT04810055 T AT 04810055T AT 04810055 T AT04810055 T AT 04810055T AT E536178 T1 ATE536178 T1 AT E536178T1
Authority
AT
Austria
Prior art keywords
methionine
mucositis
treatment
prevention
therapeutic use
Prior art date
Application number
AT04810055T
Other languages
English (en)
Inventor
Kathleen C M Campbell
Original Assignee
Univ Southern Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern Illinois filed Critical Univ Southern Illinois
Application granted granted Critical
Publication of ATE536178T1 publication Critical patent/ATE536178T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04810055T 2003-10-27 2004-10-27 Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis ATE536178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/694,436 US20050090551A1 (en) 2003-10-27 2003-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis
PCT/US2004/035626 WO2005039554A2 (en) 2003-10-27 2004-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis

Publications (1)

Publication Number Publication Date
ATE536178T1 true ATE536178T1 (de) 2011-12-15

Family

ID=34522601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04810055T ATE536178T1 (de) 2003-10-27 2004-10-27 Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis

Country Status (8)

Country Link
US (1) US20050090551A1 (de)
EP (1) EP1677775B1 (de)
JP (1) JP4884974B2 (de)
AT (1) ATE536178T1 (de)
AU (1) AU2004283756B2 (de)
CA (1) CA2543870C (de)
ES (1) ES2376102T3 (de)
WO (1) WO2005039554A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071230B2 (en) * 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
EP2001460A4 (de) * 2006-03-28 2011-01-12 Novus Int Inc Zusammensetzungen zur förderung des haarwachstums
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
MX2010008050A (es) 2008-01-22 2011-02-23 Araim Pharmaceuticals Inc Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
CA2716576A1 (en) 2008-03-07 2009-09-11 Nageswara R. Palepu Fulvestrant formulations
CN102481278B (zh) * 2009-09-14 2014-04-16 株式会社资生堂 紫外线损伤减轻组合物
EP2484353A4 (de) * 2009-09-30 2013-04-17 Shiseido Co Ltd Oral einnehmbare zusammensetzung zur linderung durch ultraviolettstrahlung herbeigeführter schäden
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
JP5578997B2 (ja) * 2010-09-16 2014-08-27 国立大学法人 大分大学 がん化学療法誘発脱毛に対する抗脱毛用組成物
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
EP3836940A4 (de) 2018-08-14 2022-05-18 Tosk, Inc. Verfahren und zusammensetzungen zur verminderung der durch fluorouracil induzierten toxizität
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
AU2021306230A1 (en) 2020-07-07 2023-03-02 Tosk, Inc. Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
CN114051974B (zh) * 2021-11-10 2023-01-17 广西医科大学 一种肝癌模型及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652290A (en) * 1970-08-10 1972-03-28 Merck & Co Inc Beverages containing stabilized vitamin c
US3962429A (en) * 1973-08-01 1976-06-08 Chugai Seiyaku Kabushiki Kaisha Method for reducing side effects of aminoglycoside antibiotics and composition therefor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5122369A (en) * 1990-03-30 1992-06-16 Harmony Health Products, Inc. Nutrient composition for preventing hair loss
AU703079B2 (en) * 1994-07-01 1999-03-11 Procter & Gamble Company, The Desquamation compositions
JPH08190187A (ja) * 1995-01-11 1996-07-23 Canon Inc 情報記録装置
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
DK0930877T3 (da) * 1996-10-03 2006-08-21 Univ Southern Illinois D-methionin til formindskelse af toksiciteten af platinholdige antitumorforbindelser
CA2320202C (en) * 1998-02-13 2010-09-14 Nutramax Laboratories, Inc. Agents and methods for protection, treatment and repair of connective tissue
EP1194161B1 (de) * 1999-07-13 2005-11-23 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
ATE355087T1 (de) * 2000-10-24 2006-03-15 Cis Bio Int Stabilisierung von radiopharmazeutischen zusammensetzungen mit einem hydrophilen thioether oder einem hydrophilen 6-hydroxy-chroman
ATE316786T1 (de) * 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
IL157367A0 (en) * 2001-03-09 2004-02-19 Nestle Sa Composition improving age-related physiological deficits and increasing longevity
AU2002352982B2 (en) * 2001-11-29 2008-03-06 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
WO2004080429A2 (en) * 2003-03-13 2004-09-23 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
EP1796635A2 (de) * 2004-09-14 2007-06-20 Molecular Therapeutics, Inc. D-methionin-formulierung mit verbesserten biopharmazeutischen eigenschaften

Also Published As

Publication number Publication date
EP1677775A2 (de) 2006-07-12
AU2004283756A2 (en) 2005-05-06
WO2005039554A2 (en) 2005-05-06
CA2543870C (en) 2013-03-12
EP1677775B1 (de) 2011-12-07
CA2543870A1 (en) 2005-05-06
US20050090551A1 (en) 2005-04-28
AU2004283756B2 (en) 2010-07-29
WO2005039554A3 (en) 2005-12-15
ES2376102T3 (es) 2012-03-09
JP4884974B2 (ja) 2012-02-29
AU2004283756A1 (en) 2005-05-06
JP2007509955A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
DE69400353D1 (de) Schlankmachende Zusammensetzung
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
EA201270298A1 (ru) Способ лечения злокачественной опухоли
ATE374605T1 (de) Transdermale verabreichung von (r)-3,3- diphenylpropylamin-monoestern
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
RU2003113210A (ru) Лечение раковых заболеваний
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
BR0315374A (pt) Compostos orgânicos
RU2488414C1 (ru) Способ лечения профессионального миофиброза верхних конечностей
ATE458477T1 (de) Pharmazeutische zusammensetzung enthaltend in assoziation ubidecarenon, dexpanthenol und chlorhexidine oder eines seiner pharmazeutischen unbedenklichen salze zur anwendung auf der haut